Integrating Efficacy and Effectiveness Evidence from Randomized Controlled Trials and Real-World Studies of Inhaled Corticosteroid/Long-Acting β 2 -Agonist Therapies in Moderate Asthma
Аннотация
Introduction Inhaled corticosteroid/long-acting β 2 -agonist (ICS/LABA) combinations are a cornerstone of moderate asthma management that have been approved to treat asthma on the basis of results from randomized controlled trials (RCTs). However, efficacy observed in RCTs does not necessarily translate directly into effectiveness, partly because of lower adherence or persistence and less intensive follow-up structures in routine clinical practice. This has driven interest in real-world evidence (RWE) studies and pragmatic RCTs as sources of evidence complementary to conventional RCTs. We aimed to assess how considering multiple study types could enhance our understanding of ICS/LABA therapy in asthma management. Methods We undertook a targeted literature search of PubMed/MEDLINE of RCTs (conventional and pragmatic) and RWE studies evaluating ICS/LABA therapies in patients with moderate asthma through a structured screening approach. Results Twenty two publications were selected for descriptive comparison. Similar results for ICS/LABA therapies were reported across studies, supporting the generalizability of conventional RCT findings to routine clinical practice. Reported severe exacerbation rates per patient per year (PPPY) were approximately 0.14–0.31 PPPY in conventional RCTs, 0.12–0.47 PPPY in pragmatic RCTs, and overall exacerbation rates 0.07–0.18 in RWE studies, with lower rates reported for ICS/LABA interventions than comparator. Across studies, approximately half of patients reported improvements in asthma control following ICS/LABA treatment. Conventional RCTs reported high treatment persistence and generally higher treatment adherence than pragmatic RCTs or RWE studies; however, the perceived impacts of adherence on treatment effects were mixed between studies. Where reported, lung function data indicated improvements following ICS/LABA treatment, although RWE data were limited. Conclusion Our findings support the view that conventional RCTs, pragmatic RCTs, and RWE studies represent complementary components of a unified evidence continuum that should be considered together to optimize patient care. Integrating evidence across this continuum provides a more comprehensive understanding of ICS/LABA therapy and may better inform personalized treatment decisions in asthma.